Bristol-Myers reports results from Phase 3 Yervoy study Bristol-Myers Squibb Company announced results from a Phase 3 randomized, double blind study demonstrating that Yervoy 10 mg/kg significantly improved recurrence-free survival vs. placebo for patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection, an adjuvant setting. A twenty-five percent reduction in the risk of recurrence or death was observed. At three years, an estimated 46.5% of patients treated with Yervoy were free of disease recurrence compared to an estimated 34.8% of patients on placebo. The median RFS was 26.1 months for Yervoy vs. 17.1 months for placebo, with a median follow-up of 2.7 years. The data will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology at 3:00 p.m. CDT today and highlighted at a Congress press briefing.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.